<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114672">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610362</url>
  </required_header>
  <id_info>
    <org_study_id>RC5504</org_study_id>
    <nct_id>NCT01610362</nct_id>
  </id_info>
  <brief_title>Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response</brief_title>
  <official_title>Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Saovabha Memorial Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen Saovabha Memorial Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dosage of rabies immune globulin was calculated from the victim's body weight, then the
      amount of rabies immune globulin would be injected as much as possible to all of the wounds.
      Increase dosage of rabies immune globulin was needed in situation of multiple severe
      bite-wounds especially among children whose had lower body weight than adults. Our study
      would be conducted in order to determine whether the increase dosage of rabies immune
      globulin would interfere with the protective antibody levels against rabies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Controlled trial study.

        -  All 50 volunteers who had never had rabies immunization would be enrolled and
           designated into 2 groups.

      group 1 : 15 Healthy volunteers age 18 - 60 yr who were attacked by mammals, possible
      exposed to rabies and had WHO category III exposure, all receive standard post - exposure
      rabies treatment with 5-dose intramuscular rabies vaccine on day 0,3,7,14,28 and 20 IU/kg of
      human rabies immune globulin (HRIG).

      group 2 : 35 Healthy volunteers age 18 - 60 yr receive 5-dose intramuscular rabies vaccine
      on day 0,3,7,14,28 and 40 IU/kg of human rabies immune globulin (HRIG).

      5 cc - Blood would be drawn from all volunteers before vaccination and on day 14, 28 and 90
      for rabies neutralizing antibody titers (RNab).

      The GMTs of RNab among both groups would be analyzed and compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rabies Neutralizing antibody titers in volunteers who receive HRIG 40 IU/kg</measure>
    <time_frame>Change from baseline of Rabies Neutralizing Antibody Titers at 3 - month period</time_frame>
    <description>Rabies Neutralizing antibody titers in volunteers who receive HRIG 40 IU/kg would be determined on day 0,14, 28 and 90. Rnab titers above 0.5 IU/ml would be considered as protective levels as WHO recommendation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who have Rabies Neutralizing antibody titers above protective levels.</measure>
    <time_frame>Number of participants who have Rabies Neutralizing antibody titers above protective levels at 3-month period..</time_frame>
    <description>Number of participants who have Rabies Neutralizing antibody titers above protective levels (&gt; 0.5 IU/mL as recommended by WHO)at 3-month period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>5-dose IM rabies vaccines, HRIG 20 IU/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rabies exposed victims, 5-dose IM rabies vaccine, HRIG 20 IU/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-dose IM rabies vaccines, HRIG 40 IU/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers, 5-dose IM rabies vaccine, HRIG 40 IU/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Rabies Immune Globulin</intervention_name>
    <description>HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0</description>
    <arm_group_label>5-dose IM rabies vaccines, HRIG 20 IU/kg</arm_group_label>
    <arm_group_label>5-dose IM rabies vaccines, HRIG 40 IU/kg</arm_group_label>
    <other_name>Human Rabies Immune Globulin produced by Thai Red Cross</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers age 18-60 years.

        Exclusion Criteria:

          -  received prior rabies immunization

          -  pregnancy

          -  immunocompromised conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suda Sibunruang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Saovabha Memorial Institute, Thai Red Cross Society</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suda Sibunruang, M.D.</last_name>
    <phone>+66 81 7366076</phone>
    <email>sudapunrin@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Terapong Tantawichien, M.D.</last_name>
    <phone>+66 2 252 0161</phone>
    <phone_ext>125</phone_ext>
    <email>queensaovabha@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Saovabha Memorial Institute, Thai Red Cross Society</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suda Sibunruang, M.D.</last_name>
      <phone>+66 81 7366076</phone>
      <email>sudapunrin@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Terapong Tantawichien, M.D.</last_name>
      <phone>+66 2 2520161</phone>
      <phone_ext>125</phone_ext>
      <email>queensaovabha@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Suda Sibunruang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 23, 2016</lastchanged_date>
  <firstreceived_date>May 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Saovabha Memorial Institute</investigator_affiliation>
    <investigator_full_name>Suda Sibunruang</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>rabies</keyword>
  <keyword>immunoglobulin</keyword>
  <keyword>dosage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
